Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
COPD
Brief summary
DUS1 and DUS2 are descriptive drug utilisation studies in new users of aclidinium bromide in Europe. The objectives of DUS1 and DUS2 are to describe the characteristics and patterns of use of new users of aclidinium bromide (monotherapy or in combination) and new users of other medications for chronic obstructive pulmonary disease (COPD); to evaluate the potential off-label use of aclidinium bromide; to describe users of aclidinium bromide in subgroups of patients for whom there is missing information in the risk management plan (RMP); and to establish a core cohort of new users of aclidinium bromide for the future evaluation of safety concerns described in the RMP. The data source for these studies will be the CRPD in the UK, the GePaRD in Germany, and national health databases in Denmark.
Detailed description
DUS1 will be conducted when the target number of new users of aclidinium monotherapy is reached, and DUS2 when the target number of new users of aclidinium fixed-dose combination with formoterol is reached. As this was a descriptive study no primary or secondary endpoints were specified.
Interventions
Administered as monotherapy, prescribed as recorded in the database.
DRUGAclidinium bromide/formoterol
Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
Other COPD medication including: tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database.
Sponsors
RTI Health Solutions
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients in the study will be required to meet the following criteria, as ascertained from each of the automated databases: * To have at least 1 year of enrolment in the database (DUS1 and DUS2). * To have not been prescribed aclidinium bromide as monotherapy or with concomitant use of formoterol during the 6 months before the date of first prescription of aclidinium bromide (index date) in DUS1 * To have not been prescribed aclidinium bromide as monotherapy, with concomitant use of formoterol, or as aclidinium/formoterol during the 6 months before the date of first prescription of aclidinium bromide (index date) in DUS2 The same inclusion criteria will be applied for each of the comparator drugs.
Exclusion criteria
* No age restrictions or
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Baseline frequency of patients with narrow-angle glaucoma | Baseline (date of first prescription) | — |
| Frequency of new users with BMI ranging between 25.0 and 29.99 kg/m2 (pre-obese) | From date of first prescription to 1 year of follow-up | — |
| Frequency of new users with BMI >30 kg/m2 (obese) | From date of first prescription to 1 year of follow-up | — |
| Frequency of new users with low socioeconomic status (Townsend multiple deprivation index) | From date of first prescription to 1 year of follow-up | — |
| Baseline frequency of patients with benign prostatic hyperplasia | Baseline (date of first prescription) | — |
| Baseline frequency of patients with bladder neck obstruction | Baseline (date of first prescription) | — |
| Baseline frequency of patients with urinary retention | Baseline (date of first prescription) | — |
| Baseline age of new users | Baseline (date of first prescription) | — |
| Baseline frequency of new users with a diagnosis of COPD including emphysema or chronic bronchitis | Baseline (date of first prescription) | — |
| Baseline frequency of new users with severe COPD | Baseline (date of first prescription) | COPD severity including recent exacerbations |
| Baseline frequency of new users with a history of cardiovascular disease | Baseline (date of first prescription) | Baseline history of cardiovascular diseases and baseline cardiovascular risk profile, including diabetes, recent acute myocardial infarction (AMI), unstable angina, arrhythmias, or heart failure |
| Overall comorbidity index of new users | From date of first prescription up to 1 year of follow-up | — |
| Frequency of respiratory medication use by new users | From date of first prescription to 1 year of follow-up | — |
| Baseline gender of new users | Baseline (date of first prescription) | — |
| Frequency of users of aclidinium bromide with comorbid asthma diagnoses or in the absence of other drugs or diagnoses suggestive of COPD | From date of first prescription up to 1 year of follow-up | — |
| Frequency of pregnancies during use of COPD medication | From date of first prescription up to 1 year of follow-up | — |
| Frequency of use of aclidinium bromide in the pediatric population | From date of first prescription up to 1 year of follow-up | — |
| Frequency of comorbid conditions in the paediatric population | From date of first prescription up to 1 year of follow-up | — |
| Baseline frequency of patients with renal or hepatic impairment | Baseline (date of first prescription) | — |
| Baseline frequency of patients who have experienced a recent exacerbation | Baseline (date of first prescription | — |
| Baseline frequency of patients with thyrotoxicosis or pheochromocytoma | Baseline (date of first prescription) | — |
| Frequency of previous smoking in new users | From date of first prescription to 1 year of follow-up | — |
| Frequency of current smokers in new users | From date of first prescription to 1 year of follow-up | — |
| Frequency of new users with BMI <18.50 kg/m2 (underweight) | From date of first prescription to 1 year of follow-up | — |
| Frequency of new users with BMI ranging from 18.50 to 24.99 kg/m2 (normal weight) | From date of first prescription to 1 year of follow-up | — |
| Frequency of new users with BMI >25.0 kg/m2 (overweight) | From date of first prescription to 1 year of follow-up | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average daily dose of COPD medication | From date of first prescription up to 1 year of follow-up | The daily dose for each treatment will be derived from the recorded dose or from the time between consecutive prescriptions and prescribing information (strength, number of units, and number of boxes) according to the available information in each database. |
| Adherence to COPD medication within 1 year | From date of first prescription up to 1 year of follow-up | Consecutive prescriptions are defined as those with a maximum gap of 60 days between the date of prescriptions. Proportion of patients refilling prescriptions within 60 days from the end of the previous prescription. |
| Frequency of use of concomitant medications | From date of first prescription up to 1 year of follow-up | — |
| Frequency of switching between COPD medications | From date of first prescription up to 1 year of follow-up | — |
| Total number of prescriptions | From date of first prescription up to 1 year of follow-up | — |
| Duration of COPD medication use | From date of first prescription up to 1 year of follow-up | Duration of use will be estimated through the number of consecutive prescriptions, with a maximum interval of 60 days between them, or the days of supply of each prescription, as available in each database. |
Countries
Denmark, Germany, United Kingdom
Outcome results
None listed